Shelf-life studies for medical devices demonstrate how long a product remains safe, functional, and suitable for its intended use under defined storage conditions. Unlike drugs, which follow prescriptive ICH Q1A–Q1F requirements, medical device stability is driven by risk analysis, material science, ISO 11607, ASTM F1980, and specific regulatory guidance.
Below are Q&As addressing common queries of manufacturers on stability testing and shelf-life.
Q: Is a shelf life required for all medical devices?
A: No. The need for a shelf life depends on susceptibility to degradation and the risks if the device fails.
When a shelf life/expiry is usually required:
- Sterile devices: Sterile disposables, implants, and other products whose safety depends on maintained sterility generally require a validated shelf life and labelled expiry.
- Devices with degradable/unstable components: Drug–device combinations, gels, adhesives, absorbable components, and many polymer systems typically need a defined shelf life supported by stability or aging data.
Devices that may not carry a traditional shelf life:
- Durable, non‑sterile, inherently stable devices (e.g., many reusable instruments, capital equipment) may not need a “use‑by” date but do need a stated lifetime/service life and conditions for safe use and maintenance.
- For these, regulators focus on expected lifetime in use, preventive maintenance, maximum cycles, and retirement criteria rather than storage time before first use.
What regulators consistently expect:
- Assess and document how storage conditions affect each device, then decide whether an explicit shelf life is needed based on risk, material behaviour, packaging, and intended use.
- Where you claim a shelf life or specify storage limits, support them with evidence (testing, literature, or justified rationale) and appropriate labelling (expiry date, storage conditions, and/or lifetime in use).
Q: Is stability testing required only if a device has a claimed shelf life?
A: No. Stability/aging studies are the main tool to decide whether a shelf life is needed and to define safe storage and handling for all devices, not just those with an explicit expiry date.
- The formality of stability testing scales with risk: sterile single‑use and time‑sensitive products usually need formal aging studies; very stable, non‑sterile, durable devices may rely more on engineering justification and limited verification—but not on zero data.
Q: Are stability studies required only on terminally sterilized devices?
A: No. Any claimed shelf life must be justified with evidence that the device remains within specification under labelled storage conditions, regardless of sterilization status.
Why shelf‑life studies can be necessary for non‑terminally sterilized products:
- Functional and material degradation
Even non‑sterile components can degrade and fail over time. Stability work assesses whether physical, chemical, or performance characteristics change under storage, including interactions between components in combination products. - Microbiological control
Microbiologically controlled, non‑sterile products (e.g., certain IVDs) require stability testing to show microbial limits remain acceptable and preservatives remain effective over the claimed period. - Storage and handling guidelines
Stability information defines storage instructions and acceptable environmental limits (temperature, humidity, light, etc.) under which safety and performance are assured. - Regulatory expectations and exceptions
Regulators expect manufacturers to determine whether their device is susceptible to time‑dependent degradation and, where relevant, to provide data supporting the proposed expiration date.
In some cases, assigning a shelf life may not be reasonable if time‑dependent degradation is unlikely and the consequences of failure are low. For very stable, inert devices (e.g., solid metal tools in robust packaging) a science‑ and risk‑based justification with limited verification may be sufficient, provided the rationale and supporting data are documented.
Q: What temperature and humidity conditions are used for real‑time and accelerated stability testing?
A: Conditions are selected case‑by‑case using ASTM F1980, ICH concepts for combinations, and device‑specific risk assessment.
- Real‑time (long‑term) studies
- Typically, at ambient conditions representing actual storage, often around 20–25°C; using 25°C is a conservative default.
- For drug‑device and similar products, ICH‑style 25°C ± 2°C / 60% ± 5% RH is common.
- If labelled for special storage, long‑term conditions change accordingly:
- Refrigerated: about 5°C ± 3°C.
- Frozen: about −20°C ± 5°C.
- Accelerated studies
- Elevated temperatures simulate long‑term aging in shorter time using Arrhenius/Q10 concepts.
- The accelerated temperature should reflect device and packaging material limits and is commonly ≤ 60°C; higher temperatures require strong justification because polymers can show non‑linear behaviour.
- The selected temperature must remain below critical transitions such as glass transition (Tg) or melting temperature (Tm).
- For many combination products, ICH accelerated conditions (40°C ± 2°C / 75% ± 5% RH) are used; if 40°C approaches a material transition, intermediate conditions (e.g., 30°C / 65% RH) may be chosen instead.
Humidity:
- For sterile barrier systems, ASTM F1980 does not use humidity in the calculation of accelerated aging time, but humidity control may be applied to prevent material damage (e.g., delamination).
- Typical humidity tolerance is ± 5% RH; temperature tolerance is usually ± 2°C.
Q: How many time points are needed?
A: There is no fixed ICH‑like requirement, but common patterns (adapted to risk) are:
- Real‑time: at least initial and end of claimed shelf life, often with 1–2 intermediate points for longer claims (e.g., 0, 6, 12, 24, 36 months for a 3‑year shelf life).
- Accelerated: initial plus one or more points sufficient to demonstrate worst‑case behaviour or support kinetic modelling (e.g., 0 and a single terminal time matching the intended real‑time equivalent).
- Drug–device combinations aligned with ICH often use typical ICH schedules (e.g., 0, 3, 6, 9, 12 months) and overlay device‑specific tests at the same time points.
Q: How many batches and samples are needed?
A: Device programs should address lot‑to‑lot variability and worst‑case configurations.
Typical practice:
- 2–3 production‑equivalent batches, including worst‑case materials, processes, or sterilization parameters, particularly for sterile or high‑risk devices.
- For packaging/sterility shelf life (ISO 11607 / ASTM F1980), multiple packaged units per batch and time point to cover integrity, strength, and functional tests with statistically meaningful sample sizes.
- Sample sizes should be justified statistically (confidence/acceptance criteria, variability, criticality), not chosen arbitrarily.
Q: How are stability tests different for drug–device combination products?
A: You must meet both drug and device expectations in an integrated program.
- Drug component: ICH Q1A(R2)–Q1F stability (assay, degradation products, dissolution or delivery profile, particulates, pH, preservatives, microbiology, etc.).
- Device component: aging of the device and packaging (functionality over time, activation force, mechanical integrity, sterility or microbiological quality, container‑closure integrity, etc.).
Key elements:
- One integrated protocol with both drug and device endpoints at each time point.
- Use ICH‑style conditions and schedules where the primary regulation is medicinal (e.g., 25°C / 60% RH long‑term; 40°C / 75% RH accelerated).
- Include simulated‑use testing at relevant intervals to show that delivery and functionality remain acceptable as the product ages.
Q: Should we test at both lower and upper ends of the storage range?
A: You must show suitability across the labelled storage range, but you often test worst‑case rather than fully duplicating programs.
Common practice:
- Select worst‑case conditions—usually the upper temperature/humidity for many materials; for some plastics/adhesives, very low temperatures or temperature cycling can also be critical.
- If the labelled range is wide (e.g., 5–40°C), either justify why upper‑bound plus accelerated is worst case, or use bracketing (limited testing at both extremes) where justified.
- A full, mirrored program at both extremes is rarely necessary if your risk analysis and material knowledge clearly identify one side as worst‑case and this rationale is documented.
Examples:
- Intraocular lenses may require assessment at sub‑zero and elevated temperatures (around 50°C) because freezing and heat can change lens structure.
- IVDs labelled 2–8°C may need data showing stability across that range and demonstrating the impact of out‑of‑range shipping excursions (e.g., −5°C or 37°C).
- Aqueous or high‑water products should address water loss, phase changes, or freezing effects.
Q: Is accelerated stability alone sufficient, without real‑time?
A: Generally, no for sterile and higher‑risk devices. Accelerated data alone are usually treated as provisional.
Practical approach:
- Use accelerated aging to support initial release and a tentative shelf life.
- Run real‑time studies in parallel under labelled conditions and confirm or refine the shelf life when enough real‑time data are available.
Q: What is the Q10 theory?
A: Q10 describes how reaction rate changes with temperature for a given process. A 10°C change leads to a predictable factor change in reaction rate.
- Q10 must be selected conservatively unless strong evidence supports a higher value.
- Q10 = 2.0 is the most common conservative factor for medical device sterile barrier systems.
- Q10 ≈ 1.8 is often cited for some contact lens and contact lens solutions.
- Higher values (e.g., 2.2–2.5) may be used only when the system is well‑characterized and the damage mechanisms are well understood.